Parkinson's Disease Psychosis (PDP) Market valued at USD 1.25 billion in 2024 and is projected to reach USD 2.15 billion by 2034

Market Overview
The Parkinson's Disease Psychosis (PDP) Market was valued at USD 1.25 billion in 2024 and is projected to reach USD 2.15 billion by 2034, expanding at a CAGR of 5.6% during the forecast period.
Parkinson's disease psychosis is a common non-motor complication affecting up to 50-60% of patients in advanced stages. It manifests as hallucinations, delusions, visual distortions, and altered perceptions-significantly impacting quality of life, caregiver burden, and long-term outcomes.

Growing global prevalence of Parkinson's disease, rising awareness of psychosis symptoms, increasing adoption of targeted atypical antipsychotics, and improvements in neuropsychiatric care are driving market growth. The availability of selective serotonin inverse agonists and ongoing research in neurocircuit modulation further shape the market landscape.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71916

Market Dynamics
Drivers
• Rising global burden of Parkinson's disease, especially among older adults.
• Increasing recognition of psychosis as a major Parkinson's complication that requires targeted therapy.
• Growing use of FDA-approved treatments such as pimavanserin, which provides symptom control without worsening motor function.
• Advancements in tele-neurology enabling closer monitoring of psychiatric symptoms in PD patients.
• Improved caregiver awareness and greater willingness to report visual hallucinations and delusions.

Restraints
• High cost of branded antipsychotic therapies such as pimavanserin.
• Limited therapeutic options specifically approved for PDP.
• Risk of adverse effects when traditional antipsychotics are used, including motor symptom worsening.
• Underreporting of psychosis symptoms due to stigma or fear of institutionalization.
• Limited access to specialized neuropsychiatry care in developing regions.

Opportunities
• Development of next-generation serotonergic modulators and neurocircuit-targeting therapies.
• Expansion of personalized treatment approaches integrating motor and psychiatric symptom management.
• Increasing use of digital cognitive and behavioral monitoring tools for real-time symptom tracking.
• Advancements in neuroprotective Parkinson's therapies that may reduce PDP onset.
• Opportunities for combination therapies targeting multiple neurotransmitter systems.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71916/parkinson-s-disease-psychosis-market

Market Growth Outlook (2024-2034)
The PDP market will increase from USD 1.25 billion in 2024 to USD 2.15 billion in 2034, supported by rising patient numbers, greater awareness of psychosis symptoms, and strong uptake of targeted atypical antipsychotics.
Future innovations in serotonergic modulation, neurocircuit therapies, and digital symptom-monitoring platforms are expected to significantly enhance patient care.

Segmentation Analysis

By Treatment Type
Targeted Antipsychotics:
• Pimavanserin, a selective serotonin inverse agonist (5-HT2A antagonist), remains the leading approved therapy for PDP.
• Novel serotonergic and sigma receptor modulators are under clinical investigation.
Conventional Antipsychotics:
• Quetiapine and clozapine are sometimes used but carry risks of sedation, agranulocytosis (clozapine), and motor worsening.
• Their role is declining as safer, PD-specific options emerge.

Adjunctive Therapies:
• Cholinesterase inhibitors and cognitive enhancers may support patients with hallucinations linked to cognitive decline.
• Deep brain stimulation (DBS) adjustments can reduce psychotic symptoms in select cases.

By End User
• Hospitals & Neurology Centers manage acute psychotic episodes and tailor long-term medication strategies.
• Movement Disorder Clinics provide integrated care addressing both motor and psychiatric symptoms.
• Home-Care Settings & Digital Health Platforms support remote monitoring, medication adherence, and caregiver guidance.
• Geriatric Care Facilities manage PDP in advanced and institutionalized PD patients.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71916

Regional Insights
North America
North America dominates the PDP market due to high PD prevalence, strong adoption of pimavanserin, better access to neuropsychiatric care, and active clinical research programs. The U.S. remains the largest contributor to global revenue.

Europe
Europe maintains a significant share driven by rising diagnosis rates, structured Parkinson's care pathways, and growing adoption of specialized antipsychotic therapies. The UK, Germany, France, Italy, and Spain are major markets.

Asia Pacific
Asia Pacific is the fastest-growing region, fueled by a rapidly aging population, increasing PD diagnosis, expanding neurology infrastructure, and rising interest in digital health tools. Countries like Japan, China, and South Korea lead regional growth.

Latin America & Middle East/Africa
These regions show steady market expansion with improving PD care access, though economic constraints and limited reimbursement remain barriers.

Competitive Landscape
The PDP market consists of pharmaceutical innovators, psychiatric therapeutics developers, and neurology-focused research organizations.
Key Companies Include:
• Acadia Pharmaceuticals
• Roche
• Novartis
• Teva Pharmaceutical Industries
• AbbVie
• Pfizer
• Eli Lilly
• Otsuka Pharmaceutical
• Lundbeck
• Johnson & Johnson
These companies are exploring serotonergic modulation, neurocircuit therapies, next-generation antipsychotics, and hybrid neuropsychiatric treatments.

Recent Developments
• Continued global expansion of pimavanserin as the first FDA-approved PDP treatment.
• Advancements in serotonin 5-HT2A/5-HT2C receptor-targeting therapies for hallucination control.
• Growth of remote neuropsychiatric assessment tools enabling early intervention.
• Increased R&D in dopaminergic-serotonergic balancing agents to better manage psychosis without motor impairment.
• Ongoing clinical research exploring combination treatments addressing both cognitive decline and psychosis in PD.

This report is also available in the following languages : Japanese (パーキンソン病精神病市場), Korean (파킨슨병 정신병 시장), Chinese (帕金森病精神病市场), French (Marché de la psychose liée à la maladie de Parkinson), German (Markt für Psychosen bei Parkinson), and Italian (Mercato della psicosi del morbo di Parkinson), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71916

Our More Reports:

Intracranial Pressure Monitoring Devices Market
https://exactitudeconsultancy.com/reports/72113/intracranial-pressure-monitoring-devices-market

Migraine Market
https://exactitudeconsultancy.com/reports/72115/migraine-market

Sacral Nerve Stimulation Devices Market
https://exactitudeconsultancy.com/reports/72117/sacral-nerve-stimulation-devices-market

Transcranial Doppler Market
https://exactitudeconsultancy.com/reports/72119/transcranial-doppler-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.